FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma